PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy. However, current immune checkpoint-based therapies are successful only in a subset of patients and acquired resistances pose addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stecher, Carmen, Battin, Claire, Leitner, Judith, Zettl, Markus, Grabmeier-Pfistershammer, Katharina, Höller, Christoph, Zlabinger, Gerhard J., Steinberger, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439058/
https://www.ncbi.nlm.nih.gov/pubmed/28588576
http://dx.doi.org/10.3389/fimmu.2017.00572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439058/
https://www.ncbi.nlm.nih.gov/pubmed/28588576
http://dx.doi.org/10.3389/fimmu.2017.00572

Ejemplares similares